Parkinson's Disease Global Clinical Trials Review, H2, 2016 - GlobalData

Parkinson's Disease Global Clinical Trials Review, H2, 2016

Parkinson's Disease Global Clinical Trials Review, H2, 2016 - GlobalData
Parkinson's Disease Global Clinical Trials Review, H2, 2016
Published Sep 30, 2016
758 pages — Published Sep 30, 2016
Price US$ 2,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GlobalData's clinical trial report, Parkinson's Disease Global Clinical Trials Review, H2, 2016' provides an overview of Parkinson's Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Parkinson's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

  
Source:
Document ID
GDHC3778CTIDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables31
  List of Figures41
Report Guidance51
Clinical Trials by Region68
  Clinical Trials and Average Enrollment by Country72
    Top Five Countries Contributing to Clinical Trials in Asia-Pacific91
    Top Five Countries Contributing to Clinical Trials in Europe101
    Top Countries Contributing to Clinical Trials in North America111
    Top Five Countries Contributing to Clinical Trials in Middle East and Africa121
    Top Five Countries Contributing to Clinical Trials in Central and South America131
Clinical Trials by G7 Countries: Proportion of Parkinson's Disease to Central Nervous System Clinical Trials141
Clinical Trials by Phase in G7 Countries151
Clinical Trials in G7 Countries by Trial Status161
Clinical Trials by E7 Countries: Proportion of Parkinson's Disease to Central Nervous System Clinical Trials171
Clinical Trials by Phase in E7 Countries181
Clinical Trials in E7 Countries by Trial Status191
Clinical Trials by Phase202
  In Progress Trials by Phase211
Clinical Trials by Trial Status221
Clinical Trials by End Point Status231
Subjects Recruited Over a Period of Time241
Clinical Trials by Sponsor Type251
Prominent Sponsors263
  Top Companies Participating in Parkinson's Disease Therapeutics Clinical Trials272
Prominent Drugs291
Latest Clinical Trials News on Parkinson's Disease3013
  Sep 29, 2016: NeuroDerm Provides Updates on ND0612 Long-Term Safety Trial and Submission of Marketing Applications301
  Sep 22, 2016: Anavex Life Sciences Drug Shows Efficacy to Support Potential Disease Modification in Parkinson s Disease301
  Sep 20, 2016: Adamas Announces Results of EASE LID 3, a Pivotal Trial of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) in Parkinson Disease Patients at the 4th World Parkinson Congress311
  Sep 19, 2016: Parkinsons disease: Prexton Therapeutics completes phase 1 clinical trial321
  Sep 19, 2016: NeuroDerm to Present ND0612L Data at 4th World Parkinson Congress Demonstrating Ease of Use of Mini-Pump Delivery System321
  Sep 19, 2016: NeuroDerm to Present ND0612H Data at 4th World Parkinson Congress331
  Sep 12, 2016: Adamas Announces Two Data Presentations on ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) at the 4th World Parkinson Congress331
  Sep 08, 2016: Diabetes drug focus of new clinical trial for Parkinson s disease341
  Sep 07, 2016: Boost Vaccination Data Encourage Continued Development of AFFiRiS Therapeutic Parkinson's Disease Vaccine Against Alpha-Synuclein341
  Aug 29, 2016: Cynapsus Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson s Disease351
  Aug 25, 2016: NeuroDerm Initiates Patient Enrollment in a Phase III Trial of ND0612L for the Treatment of Parkinson's Disease351
  Aug 19, 2016: The First Dosing of RQ-00000010 at Virginia Commonwealth University Initiated361
  Aug 15, 2016: Cynapsus Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson s Disease Clinical Study Allowing for At-Home Titration361
  Aug 12, 2016: Cynapsus Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson's Disease371
  Aug 09, 2016: Voyager Therapeutics Initiates Third Cohort in Ongoing Phase 1b Clinical Trial of VY-AADC01 in Advanced Parkinson s Disease381
  Jul 28, 2016: International Stem Cell Announces Successful Cell Transplantation for the First Patient in Phase 1 Clinical Trial of ISC-hpNSC381
  Jul 26, 2016: NeuroDerm Announces Start of Bioequivalence Trial in Healthy Volunteers of ND0701, a New Continuous Subcutaneously Delivered Apomorphine Product Candidate for the Treatment of Advanced Parkinson Disease391
  Jul 18, 2016: Cynapsus Therapeutics Provides European Clinical Update for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease391
  Jul 18, 2016: Cynapsus Therapeutics Announces Positive Phase 3 Dose Titration Phase Results with APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease401
  Jul 12, 2016: Leukemia drug shows early promise for treating Parkinsons disease and dementia411
  Jul 07, 2016: Parkinsons UK &MedGenesis Therapeutix announce top-line results of Phase 2 GDNF safety and efficacy clinical trial421
Clinical Trial Profile Snapshots43712
Appendix7554
  Abbreviations7551
  Definitions7551
  Research Methodology7561
  Secondary Research7561
  About GlobalData7571
  Contact Us7571
  Disclaimer7571
  Source7581

Table Of Contents

GlobalData—GlobalData uses proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries.

About the Author


Cite this Report

  
MLA:
GlobalData. "Parkinson's Disease Global Clinical Trials Review, H2, 2016" Sep 30, 2016. Alacra Store. May 14, 2025. <http://www.alacrastore.com/storecontent/GlobalData/Parkinson-s-Disease-Global-Clinical-Trials-Review-H2-2016-2085-24099>
  
APA:
GlobalData. (2016). Parkinson's Disease Global Clinical Trials Review, H2, 2016 Sep 30, 2016. New York, NY: Alacra Store. Retrieved May 14, 2025 from <http://www.alacrastore.com/storecontent/GlobalData/Parkinson-s-Disease-Global-Clinical-Trials-Review-H2-2016-2085-24099>
  
US$ 2,500.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.